Fennec Pharmaceuticals (FENC) Equity Average: 2011-2025
Historic Equity Average for Fennec Pharmaceuticals (FENC) over the last 15 years, with Sep 2025 value amounting to -$6.0 million.
- Fennec Pharmaceuticals' Equity Average fell 83.13% to -$6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.0 million, marking a year-over-year decrease of 83.13%. This contributed to the annual value of -$8.7 million for FY2024, which is 23.28% down from last year.
- As of Q3 2025, Fennec Pharmaceuticals' Equity Average stood at -$6.0 million, which was up 10.40% from -$6.7 million recorded in Q2 2025.
- Fennec Pharmaceuticals' Equity Average's 5-year high stood at $27.0 million during Q1 2021, with a 5-year trough of -$8.5 million in Q2 2023.
- In the last 3 years, Fennec Pharmaceuticals' Equity Average had a median value of -$5.0 million in 2023 and averaged -$4.1 million.
- As far as peak fluctuations go, Fennec Pharmaceuticals' Equity Average surged by 165.55% in 2021, and later slumped by 4,371.23% in 2024.
- Quarterly analysis of 5 years shows Fennec Pharmaceuticals' Equity Average stood at $20.6 million in 2021, then slumped by 72.53% to $116,500 in 2022, then slumped by 975.97% to -$1.0 million in 2023, then crashed by 441.06% to -$5.5 million in 2024, then slumped by 83.13% to -$6.0 million in 2025.
- Its last three reported values are -$6.0 million in Q3 2025, -$6.7 million for Q2 2025, and -$5.9 million during Q1 2025.